| Rheumatoid arthritis patients | ||
---|---|---|---|
 | Primary cohort (n= 220) | Validation cohort (n= 127) | Longitudinal cohort (n= 31) |
Age (years) | 61 ± 12 | 59 ± 13 | 53 ± 13 |
Sex female | 176 (80) | 103 (81) | 21 (68) |
Disease-related characteristics | Â | Â | Â |
   Disease duration (years) | 17 ± 12 | 10 ± 10 | 13 ± 13 |
   Rheumatoid factor-positive (%) | 126 (79) | n/a | 23 (74) |
   Erythrocyte sedimentation rate (mm/hour) | 12 (7 to 26) | 22 (12 to 38) (n = 112) | 10 (4 to 16) |
   C-reactive protein (mg/l) | 3 (3 to 12) | 5 (3 to12) | 18 (9 to 33) |
   DAS28 | 3.29 ± 1.26 | n/a | 4.32 ± 0.87 |
   HAQ | 1.6 ± 0.9 | n/a | 2.19 ± 0.42 |
Classical CVD risk factors | Â | Â | Â |
   Body mass index | 29 ± 6 | 33 ± 12 | 29 ± 6 |
   Current smokers | 33 (15) | 40 (31) | 7 (23) |
   Diabetes mellitus | 17 (8) | 10 (8) | 0 (0) |
   Dyslipidaemia | 60 (27) | 30 (24) | 7 (23) |
   SBP (mmHg) | 134 ± 18 | 134 ± 18 | 130 ± 14 |
   DBP (mmHg) | 79 ± 11 | 79 ± 10 | 81 ± 11 |
   Heart rate (beats/minute) | 74 ± 13 | 68 ± 11 | 73 ± 12 |
   Total cholesterol (mmol/l) | 5.0 ± 1.0 | 5.2 ± 0.9 (n = 114) | 5.0 ± 0.9 |
   HDL (mmol/l) | 1.5 ± 0.4 | 1.6 ± 0.7 (n = 102) | 1.5 ± 0.3 |
   Triglycerides (mmol/l) | 1.3 ± 0.6 | 1.2 ± 0.4 (n = 95) | 1.5 ± 0.6 |
   TC:HDL ratio | 3.5 ± 1.1 | 3.5 ± 0.8 (n = 102) | 3.5 ± 0.8 |
RA disease-specific medications | Â | Â | Â |
   Methotrexate | 124 (65) | 76 (60) | 19 (61) |
   Sulfasalazine | 44 (24) | 0 | 5 (16) |
   Hydroxychloroquine | 50 (28) | 0 | 4 (13) |
   Leflunomide | 15 (9) | 16 (13) | 0 (0) |
   Prednisolone | 48 (26) | 85 (67) | 6 (19) |
   NSAID | 34 (20) | 3 (2) | 6 (19) |
   COX II inhibitors | 12 (7) | 0 (0) | 2 (7) |
   Analgesic | 74 (40) | n/a | 8 (26) |
   Folic acid | 118 (63) | 63 (50) | 16 (52) |
   Anti-TNFα | 44 (20) | 51 (40) | -- |
CVD medications | Â | Â | Â |
   Anti-hypertensive | 67 (36) | 68 (66) | 6 (19) |
   Anti-hypercholesterolemics | 57 (31) | 23 (18) | 4 (13) |
   Beta-blocker | 20 (11) | 28 (22) | 2 (7) |
   Calcium channel-blocker | 24 (14) | 19 (15) | 0 (0) |
Pulse wave analysis | Â | Â | Â |
   Ejection duration (m/second) | 312 ± 27 | 331 ± 26 | 320 ± 25 |
   Pulse pressure (mmHg)b | 46 ± 13a | 54 ± 14 | - |
   Mean pressure (mmHg) | 99 ± 12 | 97 ± 11 | 99 ± 10 |
   Tension time index | 2,424 ± 402 | 2,485 ± 441 | 2,359 ± 368 |
   Diastolic time index | 3,493 ± 462 | 3,443 ± 472 | 3,523 ± 651 |
   SEVR (%) | 148 ± 27 | 142 ± 25 | 157 ± 33 |
   Augmentation index (%) | 33 ± 9 | 34 ± 10 | 32 ± 9 |